Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis
| Autor: | R.J. Weiss, Richard E Gliklich, Erik A. Imel, Kathryn Starzyk, Yamei Wang, S.A. Williams |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Abaloparatide Database analysis medicine.medical_treatment Osteoporosis Urology 030209 endocrinology & metabolism Medicare 03 medical and health sciences 0302 clinical medicine Bone Density Internal medicine hemic and lymphatic diseases Teriparatide Medicine Humans neoplasms Osteoporosis Postmenopausal Aged Patient characteristics Bone Density Conservation Agents business.industry Parathyroid Hormone-Related Protein Infant Bisphosphonate medicine.disease Rheumatology United States Denosumab Real-world Cohort Original Article Female 030101 anatomy & morphology business medicine.drug |
| Zdroj: | Osteoporosis International |
| ISSN: | 1433-2965 0937-941X |
| Popis: | Summary We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database. Differences were noted in sex, age, pathologic fractures, comorbidity index, and prior bisphosphonate use for patients initiating ABL and TPTD compared with those receiving DMAB. Introduction To characterize patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) treatment in a real-world clinical setting. Methods Patients aged ≥ 18 years initiating ABL, TPTD, or DMAB between May 1, 2017, and September 24, 2018 (without receiving the same drug in the previous 12 months), were identified using the OM1 Data Cloud, which contains medical and pharmacy claims from approximately 200 million US patients. The index date was the date of initial prescription or dispensing for ABL, TPTD, or DMAB during the study period. Results During the study period, 2666 patients initiated ABL, 9210 TPTD, and 116,718 DMAB. Mean age (standard deviation) was 69.2 (10.6) years for the ABL cohort, 68.6 (11.3) for TPTD, and 72.1 (10.2) for DMAB (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink